Monotherapy in Parkinson's disease
Adult: As hydrochloride: Initially, 2.5 mg tid; increase gradually depending on clinical response to a total of 15-60 mg daily in divided doses.
|
Chỉ định và Liều dùng
Oral
Monotherapy in Parkinson's disease Adult: As hydrochloride: Initially, 2.5 mg tid; increase gradually depending on clinical response to a total of 15-60 mg daily in divided doses.
|
|
Chống chỉ định
Closed-angle glaucoma, myasthenia gravis; paralytic ileus; pyloric stenosis and prostatic hyperplasia; hyperthyroidism; tachycardia.
|
|
Thận trọng
Down's syndrome. Child. Acute MI; cardiac insufficiency; pyrexia. Severe hepatic impairment and renal failure. Pregnancy and lactation.
|
|
Tác dụng không mong muốn
Dryness of the mouth, constipation, nausea, asthenia, vertigo, blurred vision, ataxia, fever, headache, rash, acute glaucoma.
|
|
Quá liều
Symptoms: Dilated and sluggish pupils, warm and dry skin, facial flushing, dryness of mouth, pharynx, nose and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, seizures.
|
|
Tương tác
Effects may be enhanced by other drugs with antimuscarinic properties e.g. amantadine, antihistamines, phenothiazine antipsychotics and TCAs. MAOIs may possibly enhance antimuscarinic effects. May affect the absorption of other drugs. Antimuscarinics and parasympathomimetics may counteract each other's effects.
|
|
Tác dụng
Description:
Mechanism of Action: Metixene is a tertiary antimuscarinic with both central and peripheral actions. It also has antihistaminic and direct antispasmodic effects. Pharmacokinetics: Absorption: Absorbed from the GI tract. Metabolism: Hepatic via sulfoxydation and N-demethylation. Excretion: Via urine. |
|
Phân loại MIMS
|